Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MiNK Therapeutics, Inc. Director's Dealing 2021

Oct 21, 2021

34471_dirs_2021-10-20_0d239b4d-ae49-496c-9ff4-60ed2275afcc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2021-10-13

Reporting Person: FLAMENBAUM WALTER MD (Director)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $0.01 2029-11-14 Common Stock (166980) Direct
Stock Option (Right to Buy) $0.01 2030-01-30 Common Stock (139150) Direct
Stock Option (Right to Buy) $3.03 2031-02-11 Common Stock (41745) Direct

Footnotes

F1: The vesting of all such options was accelerated on March 31, 2021 and were fully-vested as of such date.